Omar I Khan
Overview
Explore the profile of Omar I Khan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bensken W, Vaca G, Williams S, Khan O, Jobst B, Stange K, et al.
Seizure
. 2023 Jul;
110:169-176.
PMID: 37393863
Purpose: We used a machine learning approach to identify the combinations of factors that contribute to lower adherence and high emergency department (ED) utilization. Methods: Using Medicaid claims, we identified...
2.
Bensken W, Fernandez Baca Vaca G, Alberti P, Khan O, Ciesielski T, Jobst B, et al.
Neurol Clin Pract
. 2023 Mar;
13(1):e200101.
PMID: 36865639
Background And Objectives: Being on a newer, second-, and third-generation antiseizure medication (ASM) may represent an important marker of quality of care for people with epilepsy. We sought to examine...
3.
Bensken W, Alberti P, Khan O, Williams S, Stange K, Vaca G, et al.
Epilepsy Res
. 2022 Nov;
188:107038.
PMID: 36332544
Epilepsy is a disease where disparities and inequities in risk and outcomes are complex and multifactorial. While most epilepsy research to date has identified several key areas of disparities, we...
4.
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies
Shalabi H, Martin S, Yates B, Wolters P, Kaplan C, Smith H, et al.
Neuro Oncol
. 2022 Feb;
24(9):1584-1597.
PMID: 35148417
Background: Neurotoxicity is an established toxicity of CD19 CAR T-cell therapy; however, there is little information on neurotoxicity in children, adolescents, and young adults (CAYA) receiving CD19/CD28ζ CAR T-cells for...
5.
Brownrout J, Norato G, Bensken W, Squirewell C, Gordon T, Heiss J, et al.
Neurology
. 2021 Oct;
97(20):e2039-e2045.
PMID: 34670817
Objective: To determine if maintaining continuity in research topic and method from early to late career yields a greater likelihood of physician-scientists' research career success; that is, achieving research independence...
6.
Cordes L, Davarpanah N, Reoma L, Gasmi B, Quezado M, Khan O, et al.
Clin Case Rep
. 2020 Jan;
8(1):24-32.
PMID: 31998480
We report a case of nivolumab-induced delayed-onset aseptic meningitis and a case of limbic encephalitis and peripheral nerve palsy with toxicity relapse 6 months after initial presentation. The atypical presentations...
7.
Reoma L, Trindade C, Monaco M, Solis J, Montojo M, Vu P, et al.
Ann Neurol
. 2019 Oct;
86(6):878-884.
PMID: 31600832
Objective: JC virus (JCV) infection is a lytic infection of oligodendrocytes in progressive multifocal leukoencephalopathy; less common forms of central nervous system manifestations associated with JCV infection include granule cell...
8.
Bensken W, Nath A, Heiss J, Khan O
Acad Med
. 2019 Jan;
94(5):659-663.
PMID: 30640263
In academic medicine, the attrition of the physician-scientist workforce has been significantly discussed for the past three decades, with substantial attention and funding targeted to stop this attrition and attempt...
9.
Heiss J, Argersinger D, Theodore W, Butman J, Sato S, Khan O
Neurosurgery
. 2018 Nov;
85(1):E4-E15.
PMID: 30407567
Background: Minimally invasive therapies for drug-resistant epilepsy (DRE) have been advocated. A study of convection-enhanced delivery (CED) of muscimol, a GABAA receptor agonist, was previously completed in non-human primates. Objective:...
10.
Bensken W, Hansen A, Norato G, Heiss J, Nath A, Khan O
Neurology
. 2018 Aug;
91(11):508-514.
PMID: 30097476
Objective: The objective of this study was to evaluate the methods by which neurology physician-scientists are quantified through applying author-level metrics to commonly used definitions when discussing funding efforts aimed...